The lack of significant impact on lipid metabolism and atherogenesis observed in LDLR-/- mice lacking apoC3 suggests that targeting apoC3 for the treatment of hyperlipidemia and CVD may require further investigation [30]. Here, APOC3 is linked to hyperlipidemia.